Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 janv. 2026 09h15 HE | Source: Psyence Biomedical Ltd.

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
05 janv. 2026 08h00 HE | Source: Compass Therapeutics

Compass Therapeutics Announces Key Leadership Appointments

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
17 déc. 2025 07h30 HE | Source: Compass Therapeutics

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
11 déc. 2025 07h30 HE | Source: Autobahn Labs

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

Autobahn Labs and Astellas form a strategic partnership to source and develop early-stage drug discovery programs from academia.
09 déc. 2025 07h00 HE | Source: ONL Therapeutics

ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science

ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
08 déc. 2025 08h00 HE | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
03 déc. 2025 09h52 HE | Source: SparkCharge

SparkCharge, MassCEC, and Zipcar Launch First Off‑Grid EV Charging Hub for Shared Mobility in Massachusetts

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- SparkCharge, the world’s largest EV fleet charging network, has partnered with the Massachusetts Clean Energy Center (MassCEC) and Zipcar, the world’s...
24 nov. 2025 10h00 HE | Source: Precedence Research

Artificial Blood Substitute Market Surges USD 62.54 Million by 2034 Amid Rising Emergencies and Innovation

Ottawa, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The global artificial blood substitute market size was valued at USD 9.7 million in 2024 and is predicted to hit around USD 62.54 million by 2034, rising at...
20 nov. 2025 07h00 HE | Source: Psyence Biomedical Ltd.

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
17 nov. 2025 08h00 HE | Source: Curium

Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts

Curium Biopharma will continue to lead discovery and new product development Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancerCurium...

Page précédente

Page suivante